2,214 Shares in Gilead Sciences, Inc. $GILD Purchased by Cypress Capital LLC

Cypress Capital LLC acquired a new position in shares of Gilead Sciences, Inc. (NASDAQ:GILD) during the 2nd quarter, HoldingsChannel reports. The institutional investor acquired 2,214 shares of the biopharmaceutical company’s stock, valued at approximately $245,000.

Several other hedge funds and other institutional investors also recently made changes to their positions in the company. EPG Wealth Management LLC raised its holdings in shares of Gilead Sciences by 2.0% during the second quarter. EPG Wealth Management LLC now owns 4,627 shares of the biopharmaceutical company’s stock valued at $513,000 after acquiring an additional 89 shares during the period. Southland Equity Partners LLC boosted its stake in Gilead Sciences by 2.9% in the 2nd quarter. Southland Equity Partners LLC now owns 3,285 shares of the biopharmaceutical company’s stock worth $364,000 after purchasing an additional 92 shares during the period. Putney Financial Group LLC grew its position in Gilead Sciences by 53.4% during the 2nd quarter. Putney Financial Group LLC now owns 270 shares of the biopharmaceutical company’s stock worth $30,000 after purchasing an additional 94 shares in the last quarter. Twelve Points Wealth Management LLC grew its position in Gilead Sciences by 1.5% during the 2nd quarter. Twelve Points Wealth Management LLC now owns 6,499 shares of the biopharmaceutical company’s stock worth $721,000 after purchasing an additional 98 shares in the last quarter. Finally, Advantage Trust Co raised its stake in Gilead Sciences by 13.6% during the 2nd quarter. Advantage Trust Co now owns 838 shares of the biopharmaceutical company’s stock valued at $93,000 after purchasing an additional 100 shares during the period. 83.67% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

Several brokerages have recently commented on GILD. Daiwa America raised Gilead Sciences from a “hold” rating to a “strong-buy” rating in a research report on Tuesday, August 19th. Cantor Fitzgerald reissued an “overweight” rating and issued a $135.00 price objective on shares of Gilead Sciences in a research note on Friday, October 31st. Wells Fargo & Company lifted their target price on Gilead Sciences from $140.00 to $145.00 and gave the company an “overweight” rating in a research note on Friday, October 31st. Needham & Company LLC reiterated a “buy” rating and issued a $133.00 target price on shares of Gilead Sciences in a report on Friday, October 31st. Finally, Royal Bank Of Canada increased their price target on shares of Gilead Sciences from $100.00 to $105.00 and gave the stock a “sector perform” rating in a research report on Friday, October 31st. One analyst has rated the stock with a Strong Buy rating, twenty-two have issued a Buy rating and three have given a Hold rating to the stock. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average target price of $127.82.

Insider Transactions at Gilead Sciences

In other news, CFO Andrew D. Dickinson sold 2,500 shares of the firm’s stock in a transaction on Wednesday, October 15th. The shares were sold at an average price of $118.08, for a total transaction of $295,200.00. Following the transaction, the chief financial officer owned 157,055 shares in the company, valued at approximately $18,545,054.40. This trade represents a 1.57% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, insider Johanna Mercier sold 28,000 shares of the company’s stock in a transaction on Friday, August 15th. The stock was sold at an average price of $118.53, for a total transaction of $3,318,840.00. Following the completion of the sale, the insider owned 114,168 shares of the company’s stock, valued at $13,532,333.04. This represents a 19.70% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders have sold a total of 71,500 shares of company stock worth $8,336,040 in the last 90 days. 0.27% of the stock is owned by insiders.

Gilead Sciences Stock Down 3.7%

GILD opened at $118.84 on Monday. Gilead Sciences, Inc. has a fifty-two week low of $86.08 and a fifty-two week high of $124.61. The business has a 50-day moving average of $116.49 and a 200-day moving average of $112.26. The company has a debt-to-equity ratio of 1.13, a current ratio of 1.32 and a quick ratio of 1.15. The company has a market capitalization of $147.46 billion, a PE ratio of 23.67, a price-to-earnings-growth ratio of 0.81 and a beta of 0.32.

Gilead Sciences (NASDAQ:GILD) last announced its quarterly earnings results on Thursday, October 30th. The biopharmaceutical company reported $2.47 EPS for the quarter, beating the consensus estimate of $2.16 by $0.31. Gilead Sciences had a return on equity of 50.99% and a net margin of 21.86%.The business had revenue of $7.77 billion during the quarter, compared to analysts’ expectations of $7.42 billion. During the same quarter in the previous year, the business posted $2.02 EPS. The firm’s quarterly revenue was up 3.0% compared to the same quarter last year. Gilead Sciences has set its FY 2025 guidance at 8.050-8.250 EPS. Equities research analysts forecast that Gilead Sciences, Inc. will post 7.95 EPS for the current fiscal year.

Gilead Sciences Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Tuesday, December 30th. Stockholders of record on Monday, December 15th will be paid a dividend of $0.79 per share. The ex-dividend date is Monday, December 15th. This represents a $3.16 annualized dividend and a dividend yield of 2.7%. Gilead Sciences’s dividend payout ratio is 48.99%.

Gilead Sciences Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.